In partnership with
Today is Monday, November 24, 2025.
The Early Bird Index today is 74.48.
New to this newsletter? Sign up here
Why Bonds are Suddenly Booming 📈
Bonds are having their best year since 2020. The recent performance of bonds and how investors should work with bonds right now are two topics discussed in a new episode of the Early Bird podcast.
Details: Lower interest rates in 2025 have fueled the performance of intermediate-term and long-term bonds this year. A bullish investor sentiment has also been a tailwind.
Powering the Story: Bonds are providing investors with a positive real yield, which is after accounting for the impact of inflation. The market hasn’t seen this support from bonds in over a generation.
Yes, But: Bonds have some drawbacks at present. U.S. treasuries, which are usually considered risk-free, are seeing higher yields due to high government debt.
Also: Corporate bonds, which are largely considered good investments, are not perfect either. There are concerns that corporations may need to refinance in the future and that some lower-quality corporate bonds could face difficulties under a recession.
Final Thoughts: How should investors approach bonds in 2026? Find out by listening to a new episode of the Early Bird podcast.
Missed OpenAI? The Clock Is Ticking on RAD Intel’s Round
Ground floor opportunity on predictive AI for ROI-based content.
RAD Intel is already trusted by a who’s-who of Fortune 1000 brands and leading global agencies with recurring seven-figure partnerships in place.
$50M+ raised. 10,000+ investors. Valuation up 4,900% in four years*.
Backed by Adobe and insiders from Google. Shares at $0.81 until Nov 20 — then the price moves. Invest now.
This is a paid advertisement for RAD Intel made pursuant to Regulation A+ offering and involves risk, including the possible loss of principal. The valuation is set by the Company and there is currently no public market for the Company's Common Stock. Nasdaq ticker “RADI” has been reserved by RAD Intel and any potential listing is subject to future regulatory approval and market conditions. Investor references reflect factual individual or institutional participation and do not imply endorsement or sponsorship by the referenced companies. Please read the offering circular and related risks at invest.radintel.ai.
Notables
Notable Earnings Today: Zoom Communications (Nasdaq: ZM), Semtech (Nasdaq: SMTC), Symbotic (Nasdaq: SYMB), Fluence (Nasdaq: FLNC), Keysight Technologies (NYSE: KEYS), Agilent (NYSE: A), Blue Bird (Nasdaq: BLBD), Central Garden (Nasdaq: CENT), Woodward (Nasdaq: WWD), Alico (Nasdaq: ALCO), BioLine RX (Nasdaq: BLRX), Corporacion America Airports (NYSE: CAAP), PennantPark Investment (NYSE: PNNT), StoneX Group (Nasdaq: SNEX), WeRide (Nasdaq: WRD).
Notable IPOs Today: Range Capital Acquisition Corp II Class A Ordinary Shares (Nasdaq: RNGT).
Notable Equity Crowdfunding Campaigns Ending Today: N/A.
Notable Economic Events Today: Industrial Production (9:15 a.m. ET).
Cardano's Security Incident
The price of the cryptocurrency Cardano $ADA.X ( ▼ 0.54% ) is down over 10% since Friday after a serious incident caused its blockchain to briefly split into two chains, disrupting the network and spurring a significant market reaction.
Details: A malicious transaction exploited a bug on Cardano’s blockchain, splitting it and creating incompatible ledgers. Several networks paused Cardano trading.
Also: The incident is so serious that the FBI is reportedly investigating it.
Price: Cardano has lost over half its value in 2025.
Final Thoughts: Caradano’s network is actively trading again since the incident, but questions remain about the long-term impacts of it.
Bayer Hits Trial Goal
On Sunday, the pharmaceutical company Bayer AG $BAYRY ( ▲ 3.39% ) announced that a Phase III study on oral FXIa inhibitor Asundexian met its primary efficacy and safety goals.
Quote: “We are excited by these positive topline findings which highlight the potential of Factor XIa inhibition as a new way to help protect patients from a recurrent stroke,” -Christian Rommel, Head of Research and Development at Bayer’s Pharmaceuticals Division.
Final Thoughts: Bayer’s stock is already up 60.73% this year.
Trends to Watch
Disbanded: DOGE 'doesn't exist' with eight months left on its charter (Reuters)
Ignoring Big Challenges: Bessent believes there won’t be a recession in 2026 but says some sectors are challenged (CNBC)
It’s a Different Market: Why the once-invincible Nvidia can’t save the AI trade (MarketWatch)
New Crypto ETFs: NYSE approves Grayscale DOGE and XRP ETFs, clearing launch for Monday (Cointelegraph)
Supply Crunch: Lenovo Stockpiling PC Memory Due to ‘Unprecedented’ AI Squeeze (Bloomberg)
Thank you for reading!
Forward to a friend and tell them to sign up here.
Pick winning stocks: Upgrade to Early Bird Prime.
Be social: Like our Facebook page and follow us on Twitter.
Want more investing tips? Listen to the podcast.
Show Your Support: Buy Me a Coffee.
Questions or comments? Hit reply to reach out.
The contents of Early Bird are intended for informational and entertainment purposes only. They do not constitute trade or investment recommendations, and they are not financial or legal advice. Readers are encouraged to consult licensed professionals for personalized guidance regarding their financial or legal situations.
